VSY Biotechnology to Launch AcrivaUD Trinova Trifocal IOL at ESCRS Meeting

October 6, 2017: By Jon Swedien
VSY's AcrivaUD Trinova Trifocal IOL

VSY’s AcrivaUD Trinova Trifocal IOL

VSY Biotechnology announced Oct. 2 it planned to launch its AcrivaUD Trinova Trifocal IOL at the 2017 meeting of the European Society of Cataract and Refractive Surgeons, being held Oct. 7-11 in Lisbon, Portugal.

The AcrivaUD (Ultra-Definition) Trinova, which has CE mark approval, is manufactured with VSY’s seamless vision technology (SVT).

SVT is a unique patent pending technique to produce an IOL optical surface that does not exhibit any sharp edges, helping reduce halos and scattered light, the company said. The lens shape is derived from sinusoidal functions and results in smoothly, varying surface profiles.

The Netherlands-based firm said the design provides the highest and most optimum light distribution, better contrast sensitivity, and enhanced depth of focus for spectacle independence at all distances.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Refocus Completes PMA Application for VisAbility as Treatment for Presbyopia

Novaliq’s NovaTears+Omega-3 Approved in Europe for Dry Eye

CooperVision Acquires Paragon Vision Sciences for $80 Million

AYOXXA Biosystems Launches Test for Biomarkers in Retinal Disease

Glaukos Announces New Patent for Glaucoma Stent Implanted in Schlemm’s Canal

Fortress Biotech Forms Tamid Bio Subsidiary; Lead Candidate is Ophthalmic Gene Therapy for MPS I

Samsung Launches App that Adjusts QLED TV Settings for Color-blind Viewers

Solar Eclipse Burns Crescent Wound in Woman’s Unprotected Retina

US Judge Refuses to Dismiss Allergan Suit against Imprimis

BioLight Sells IOPtima to Chengdu Kanghong Pharmaceutical Group for $56 Million

Regeneron Ending Eylea, Nesvacumab Combo Program

UK Retinal Drugmaker Exonate Forms Clinical Advisory Board

US FDA Approves RxSight’s Light Adjustable Lens and Light Delivery Device

EMA to Move to Amsterdam due to Brexit

First Subject Dosed in Nevakar’s Phase III Trial of NVK-002 for Myopia in Children

ProQR Doses First Patient in Phase I/II Trial for Leber’s Congenital Amaurosis 10

Aston EyeTech Raises $6.6 Million in Series A Equity Round

Ellex Raises $17.7 Million in Private Placement

Genentech’s Lampalizumab Fails Second Phase III Study in Geographic Atrophy

Judge Declares Mistrial in Corruption Trial of Melgen, Menendez

Coming soon

2017 Dry Eye Products Report: A Global Market Analysis for 2016 to 2022